Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Enterprise Value (2022 - 2025)

Taysha Gene Therapies' Enterprise Value history spans 4 years, with the latest figure at -$449000.0 for Q3 2025.

  • For Q3 2025, Enterprise Value rose 99.72% year-over-year to -$449000.0; the TTM value through Jun 2025 reached -$313.2 million, down 80.85%, while the annual FY2024 figure was -$139.5 million, 2.35% up from the prior year.
  • Enterprise Value for Q3 2025 was -$449000.0 at Taysha Gene Therapies, up from -$313.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$449000.0 in Q3 2025 and bottomed at -$313.2 million in Q2 2025.
  • The 4-year median for Enterprise Value is -$120.7 million (2024), against an average of -$117.4 million.
  • The largest annual shift saw Enterprise Value tumbled 344.68% in 2023 before it soared 99.72% in 2025.
  • A 4-year view of Enterprise Value shows it stood at -$36.9 million in 2022, then crashed by 286.67% to -$142.8 million in 2023, then grew by 2.35% to -$139.5 million in 2024, then soared by 99.68% to -$449000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Enterprise Value are -$449000.0 (Q3 2025), -$313.2 million (Q2 2025), and -$117.0 million (Q1 2025).